Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: Report of five cases

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Furuse, Tsutomu ^a   Hashimoto, Kenji ^b  

^a ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUNITRAZEPAM; FLUVOXAMINE;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DELIRIUM; DELUSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; EVENING DOSAGE; GLASGOW COMA SCALE; HUMAN; INTENSIVE CARE UNIT; JAPANESE; MALE; MINI MENTAL STATE EXAMINATION; PATIENT REFERRAL; SLEEP DISORDER;

EID: 77951124576     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-18     Document Type: Article

References (24)

1. Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Crit Care 2008, 12(Suppl 3):S3. 2391269, 18495054.
2. Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin 2008, 24:657-722. 10.1016/j.ccc.2008.05.008, 18929939.
3. Gunther ML, Morandi A, Ely EW. Pathophysiology of delirium in the intensive care unit. Crit Care Clin 2008, 24:45-65. 10.1016/j.ccc.2007.10.002, 18241778.
4. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nature Rev Neurol 2009, 5:210-220.
5. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335-2341. 10.1056/NEJMoa052827, 16319382.
6. Schneider LS, Dagernab KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943. 10.1001/jama.294.15.1934, 16234500.
7. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12:3857-3876. 10.2174/138161206778559614, 17073684.
8. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007, 131:596-610. 10.1016/j.cell.2007.08.036, 17981125.
9. Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009, 34:137-146.
10. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Sys Agents Med Chem 2009, 9:197-204.
11. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010, 3:25-36.
12. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 2007, 62:878-883. 10.1016/j.biopsych.2007.04.001, 17662961.
13. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease. Ann Gen Psychiatry 2010, 9:6. 10.1186/1744-859X-9-6, 2819237, 20148109.
14. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 1988, 23:89-97. 10.1016/0165-1781(88)90037-6, 3363018.
15. Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988, 24:689-692.
16. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974, 304:81-84.
17. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1656-1659. 10.1016/j.pnpbp.2008.06.011, 18647636.
18. Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, Shirayama Y, Iyo M, Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 2009, 279:189-193.
19. Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda K, Toyohara J, Wu J, Ishiwata K, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in human brain after single oral administration of donepezil: A positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009, 12:1127-1131. 10.1017/S1461145709990204, 19573265.
20. Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implications for future research. J Geriatr Psychiatry Neurol 1998, 11:159-161.
21. Burke WJ, Roccaforte WH, Wengel SP. Treating visual hallucinations with donepezil. Am J Psychiatry 1999, 156:1117-1118.
22. Wengel SP, Burke WJ, Roccaforte WH. Donepejil for postoperative delirium associated with Alzheimer's disease. J Am Geriatr Soc 1999, 47:379-380.
23. Byerly MJ, Christensen RC, Evans D. Delirium associated with a combination of sertraline, haloperidol, and benztropine. Am J Psychiatry 1996, 153:965-966.
24. Armstrong SC, Schweitzer SM. Delirium associated with paroxetine and benztropine combination. Am J Psychiatry 1997, 154:581-582.